BR112015010377A8 - derivados de 1-[1-(benzoil)-pirrolidina-2-carbonil]-pirrolidina-2-carbonitrila - Google Patents
derivados de 1-[1-(benzoil)-pirrolidina-2-carbonil]-pirrolidina-2-carbonitrilaInfo
- Publication number
- BR112015010377A8 BR112015010377A8 BR112015010377A BR112015010377A BR112015010377A8 BR 112015010377 A8 BR112015010377 A8 BR 112015010377A8 BR 112015010377 A BR112015010377 A BR 112015010377A BR 112015010377 A BR112015010377 A BR 112015010377A BR 112015010377 A8 BR112015010377 A8 BR 112015010377A8
- Authority
- BR
- Brazil
- Prior art keywords
- pyrrolidine
- benzoyl
- carbonyl
- carbonitrile derivatives
- carbonitrile
- Prior art date
Links
- OACPBABDSINWMY-UHFFFAOYSA-N 1-(1-benzoylpyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile Chemical class C1CCC(C#N)N1C(=O)C1CCCN1C(=O)C1=CC=CC=C1 OACPBABDSINWMY-UHFFFAOYSA-N 0.000 title abstract 2
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382446.8A EP2730571A1 (en) | 2012-11-12 | 2012-11-12 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
| PCT/EP2013/073460 WO2014072498A1 (en) | 2012-11-12 | 2013-11-11 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015010377A2 BR112015010377A2 (pt) | 2017-07-11 |
| BR112015010377A8 true BR112015010377A8 (pt) | 2018-01-16 |
Family
ID=47278735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015010377A BR112015010377A8 (pt) | 2012-11-12 | 2013-11-11 | derivados de 1-[1-(benzoil)-pirrolidina-2-carbonil]-pirrolidina-2-carbonitrila |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10125097B2 (enExample) |
| EP (2) | EP2730571A1 (enExample) |
| JP (1) | JP6203278B2 (enExample) |
| KR (1) | KR102151290B1 (enExample) |
| CN (1) | CN104903314B (enExample) |
| AU (1) | AU2013343430B2 (enExample) |
| BR (1) | BR112015010377A8 (enExample) |
| CA (1) | CA2890042C (enExample) |
| CY (1) | CY1118818T1 (enExample) |
| DK (1) | DK2917209T3 (enExample) |
| EA (1) | EA028422B1 (enExample) |
| ES (1) | ES2621672T3 (enExample) |
| HR (1) | HRP20170485T1 (enExample) |
| HU (1) | HUE032472T2 (enExample) |
| LT (1) | LT2917209T (enExample) |
| ME (1) | ME02706B (enExample) |
| MX (1) | MX367488B (enExample) |
| NZ (1) | NZ709096A (enExample) |
| PL (1) | PL2917209T3 (enExample) |
| PT (1) | PT2917209T (enExample) |
| RS (1) | RS55865B1 (enExample) |
| SI (1) | SI2917209T1 (enExample) |
| SM (1) | SMT201700202T1 (enExample) |
| WO (1) | WO2014072498A1 (enExample) |
| ZA (1) | ZA201504269B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2730571A1 (en) | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
| EP3031458A1 (en) * | 2014-12-09 | 2016-06-15 | Iproteos S.L. | Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits |
| SG11202005563YA (en) | 2017-12-15 | 2020-07-29 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| JP2022514352A (ja) | 2018-12-21 | 2022-02-10 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
| EP4178945B1 (en) * | 2020-07-07 | 2024-08-28 | Accure Therapeutics, S.L. | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
| MY208099A (en) | 2020-12-28 | 2025-04-15 | Sarawak Biodiversity Council | Compound for treating neurodegenerative diseases and its isolation method thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018891A1 (en) * | 1990-06-04 | 1991-12-12 | Pfizer Inc. | Aromatic pyrrolidine and thiazolidine amides |
| US6159938A (en) | 1994-11-21 | 2000-12-12 | Cortech, Inc. | Serine protease inhibitors comprising α-keto heterocycles |
| HUT76640A (en) * | 1995-08-17 | 1997-10-28 | Chinoin Gyogyszer Es Vegyeszet | Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use |
| DE19603510A1 (de) | 1996-02-01 | 1997-08-07 | Knoell Hans Forschung Ev | Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase |
| AU2001270627A1 (en) * | 2000-07-19 | 2002-01-30 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| FI20011466A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö |
| FI20030014A0 (fi) * | 2003-01-03 | 2003-01-03 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä |
| FI20031018A0 (fi) | 2003-07-04 | 2003-07-04 | Orion Corp | Parannus aivovammasta toipumiseen |
| JP4630192B2 (ja) | 2003-09-24 | 2011-02-09 | 日本化薬株式会社 | プロリルオリゴペプチダーゼ阻害剤 |
| US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| ES2302473B1 (es) | 2006-12-22 | 2009-06-12 | Universidad De Barcelona | Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos. |
| EP2389176A4 (en) * | 2009-01-23 | 2012-08-01 | Univ Sydney | NEW THERAPY FOR METABOLISM DISEASE |
| EP2730571A1 (en) | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
-
2012
- 2012-11-12 EP EP12382446.8A patent/EP2730571A1/en not_active Withdrawn
-
2013
- 2013-11-11 PT PT137948378T patent/PT2917209T/pt unknown
- 2013-11-11 ME MEP-2017-76A patent/ME02706B/me unknown
- 2013-11-11 HU HUE13794837A patent/HUE032472T2/en unknown
- 2013-11-11 EP EP13794837.8A patent/EP2917209B1/en active Active
- 2013-11-11 HR HRP20170485TT patent/HRP20170485T1/hr unknown
- 2013-11-11 BR BR112015010377A patent/BR112015010377A8/pt not_active Application Discontinuation
- 2013-11-11 JP JP2015541169A patent/JP6203278B2/ja active Active
- 2013-11-11 US US14/436,715 patent/US10125097B2/en active Active
- 2013-11-11 KR KR1020157015736A patent/KR102151290B1/ko active Active
- 2013-11-11 LT LTEP13794837.8T patent/LT2917209T/lt unknown
- 2013-11-11 EA EA201590942A patent/EA028422B1/ru not_active IP Right Cessation
- 2013-11-11 NZ NZ709096A patent/NZ709096A/en unknown
- 2013-11-11 CA CA2890042A patent/CA2890042C/en active Active
- 2013-11-11 PL PL13794837T patent/PL2917209T3/pl unknown
- 2013-11-11 SM SM20170202T patent/SMT201700202T1/it unknown
- 2013-11-11 RS RS20170362A patent/RS55865B1/sr unknown
- 2013-11-11 CN CN201380059126.XA patent/CN104903314B/zh active Active
- 2013-11-11 AU AU2013343430A patent/AU2013343430B2/en active Active
- 2013-11-11 DK DK13794837.8T patent/DK2917209T3/en active
- 2013-11-11 ES ES13794837.8T patent/ES2621672T3/es active Active
- 2013-11-11 MX MX2015005931A patent/MX367488B/es active IP Right Grant
- 2013-11-11 SI SI201330601A patent/SI2917209T1/sl unknown
- 2013-11-11 WO PCT/EP2013/073460 patent/WO2014072498A1/en not_active Ceased
-
2015
- 2015-06-12 ZA ZA2015/04269A patent/ZA201504269B/en unknown
-
2017
- 2017-04-06 CY CY20171100410T patent/CY1118818T1/el unknown
-
2018
- 2018-09-26 US US16/142,907 patent/US10611727B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015010377A8 (pt) | derivados de 1-[1-(benzoil)-pirrolidina-2-carbonil]-pirrolidina-2-carbonitrila | |
| EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
| BR112015002152A2 (pt) | pirróis substituídos ativos como inibidores de quinases | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| NI201300073A (es) | Compuestos y composiciones como inhibidores de la trk | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| MX2014000779A (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide. | |
| CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
| BR112015012720A2 (pt) | derivados de feniletilpiridina como inibidores de pde4 | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| PH12015500746A1 (en) | Benzamides | |
| TN2015000271A1 (en) | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| MX372740B (es) | Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak. | |
| MX2016007989A (es) | Derivados de oxindol, preparacion de los mismos y uso terapeutico en el tratamiento de enfermedades relacionadas con ampk. | |
| MX2016006603A (es) | Compuestos piperidinicos con actividad multimodal contra el dolor. | |
| PH12016500134A1 (en) | 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives | |
| MX2016010745A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina. | |
| TN2014000532A1 (en) | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | |
| MX2017007380A (es) | Compuestos organicos. | |
| BR112017024337A2 (pt) | composições farmacêuticas | |
| HK1209316A1 (en) | Substituted picolinamide kinase inhibitors | |
| BR122018070838A8 (pt) | Compostos de amidas heterocíclicas moduladoras de sting, composição contendo ditos compostos e uso dos mesmos para tratar doença mediada por sting | |
| HK1220688A1 (zh) | 有機化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |